Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096501 | 0.95 | SIGMAR1 (0.69) | SIGMAR1POLBCCR3 | |
| SCHEMBL2097491 | 0.93 | SIGMAR1 (0.66) | SIGMAR1POLBLTA4HCCR3 | |
| SCHEMBL2089113 | 0.93 | SIGMAR1 (0.72) | SIGMAR1POLBCCR3 | |
| SCHEMBL2099250 | 0.93 | SIGMAR1 (0.72) | SIGMAR1POLBCCR3 | |
| SCHEMBL662989 | 0.89 | SLC6A3 (0.68) | SIGMAR1CCR3 | |
| SCHEMBL2093251 | 0.89 | SIGMAR1 (0.71) | SIGMAR1LTA4HCCR3 | |
| SCHEMBL2097395 | 0.87 | SIGMAR1 (0.73) | SIGMAR1LTA4HCCR3 | |
| SCHEMBL2093478 | 0.87 | SIGMAR1 (0.73) | SIGMAR1LTA4HCCR3 | |
| SCHEMBL2962629 | 0.86 | SIGMAR1 (1.00) | SIGMAR1POLBLTA4HCCR3 | |
| SCHEMBL6550825 | 0.86 | SIGMAR1 (1.00) | SIGMAR1POLBLTA4HCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576941-B1 | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same | NISSHIN FLOUR MILLING CO (JP) | 1997-09-03 | — | — | EP | claimed |
| EP-0576941-A1 | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-01-05 | — | — | EP | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-4788130-A | ANTIHYDOXIC, HYPOTENSIVE, ANTIINFLAMMATORY AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-29 | — | — | US | disclosed |
| US-4735959-A | HYPOGLYCEMIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1988-04-05 | — | — | US | disclosed |
| EP-0173331-A2 | 2,3-Dihydro-1H-indene derivatives, a process for preparing them and pharmaceutical compositions containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0076996-B1 | CARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0058779-B1 | CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES | Dr. Karl Thomae GmbH (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0058779-A2 | Carboxamides, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | SIGMAR1 3525/4885POLB 3062/4885LTA4H 927/4885 |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | SIGMAR1 502/4885POLB 3251/4885LTA4H 1747/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | SIGMAR1 711/4885POLB 3578/4885LTA4H 458/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | SIGMAR1 3525/4885POLB 3062/4885LTA4H 927/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | SIGMAR1 502/4885POLB 3251/4885LTA4H 1747/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | SIGMAR1 502/4885POLB 3251/4885LTA4H 1747/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | SIGMAR1 3525/4885POLB 3062/4885LTA4H 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.